| Metro Hospice Care 31800 Northwestern Hwy, Suite #205a, Farmington Hills, MI, 48334 | |
| (248) 626-1900 |
News Archive
Brainlab, a global leader in medical technology and Mobius Imaging, developer of advanced imaging technologies, announced today CE Mark approval for Airo Mobile Intraoperative CT. The CE Mark allows Brainlab to begin installation of the systems sold in the European Union.
Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer Center.
MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.
The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).
› Verified 4 days ago
| Name | Metro Hospice Care |
|---|---|
| Location | 31800 Northwestern Hwy, Suite #205a, Farmington Hills, Michigan |
| Hospice ID | 231630 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Individual |
| Profit Type | FOR PROFIT |
| Accreditation Provider | Community Health Accreditation Partner (CHAP) |
| SSA county code | 620 |
News Archive
Brainlab, a global leader in medical technology and Mobius Imaging, developer of advanced imaging technologies, announced today CE Mark approval for Airo Mobile Intraoperative CT. The CE Mark allows Brainlab to begin installation of the systems sold in the European Union.
Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer Center.
MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.
The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
Brainlab, a global leader in medical technology and Mobius Imaging, developer of advanced imaging technologies, announced today CE Mark approval for Airo Mobile Intraoperative CT. The CE Mark allows Brainlab to begin installation of the systems sold in the European Union.
Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer Center.
MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.
The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).
› Verified 4 days ago
| Home Health Aides | 1 |
| Counselors | 0.25 |
| Licensed Practical or Vocational Nurses | 0.25 |
| Medical Social Workers | 0.25 |
| Registered Nurses | 2 |
| Other Personnel | 1 |
| Total Employees | 4.75 |
|---|
News Archive
Brainlab, a global leader in medical technology and Mobius Imaging, developer of advanced imaging technologies, announced today CE Mark approval for Airo Mobile Intraoperative CT. The CE Mark allows Brainlab to begin installation of the systems sold in the European Union.
Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer Center.
MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.
The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).
› Verified 4 days ago
| Others | 1 |
| Total Volunteers | 1 |
|---|
News Archive
Brainlab, a global leader in medical technology and Mobius Imaging, developer of advanced imaging technologies, announced today CE Mark approval for Airo Mobile Intraoperative CT. The CE Mark allows Brainlab to begin installation of the systems sold in the European Union.
Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer Center.
MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.
The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).
› Verified 4 days ago
| Metro Hospice Care Location: 31800 Northwestern Hwy, Suite #205a, Farmington Hills, Michigan, 48334 Phone: (248) 626-1900 |